Drug intelligence / Profile preview

FYB209

Development stage: Preclinical
Lead developer: Formycon

Overview

FYB209 is an undisclosed biosimilar candidate developed by Formycon. As of mid-2025, the reference product and therapeutic indication for FYB209 have not been publicly disclosed. The drug is in advanced preclinical development and is part of Formycon’s pipeline of biosimilars intended to compete with existing blockbuster biopharmaceuticals. Like other biosimilars from Formycon, FYB209 aims to provide more affordable access to high-cost biologic therapies once approved[1][2][3][4][7][9].

Beyond the preview

Go deeper on FYB209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FYB209.

Explore the full profile